Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials

References

• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib- rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–443. doi: 10.1056/NEJMoa1817073
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicenter, randomized, open-label, phase 3 trial. Lancet Oncol. 2019;20:43–56. doi: 10.1016/S1470-2045(18)30788-5
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
   PubMed Web of Science ®Google Scholar
• Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: firstline ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:5641–5654. doi: 10.1182/bloodadvances.2021006434
   PubMed Web of Science ®Google Scholar
• Molica S, Matutes E, Tam C, et al. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. Hematol Oncol. 2019;38:129–136. doi: 10.1002/hon.2695
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171–1175.
   PubMed Web of Science ®Google Scholar
• Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–1043.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in Previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452.
   PubMed Web of Science ®Google Scholar
• Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319–332.
   PubMed Web of Science ®Google Scholar
• Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919–1928.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–2294.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018 Mar 22;378(12):1107–1120. doi: 10.1056/NEJMoa1713976
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 Jun 6;380(23):2225–2236. doi: 10.1056/NEJMoa1815281
   PubMed Web of Science ®Google Scholar
• Kater A, Harrup R, Kipps TJ, et al. Final 7-year follow-up and retreatment substudy analysis of MURANO: venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hemasphere. 2023 Aug;7(Suppl):e492813f. doi: 10.1097/01.HS9.0000967716.49281.3f
   Google Scholar
• Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. Hemasphere. 2023 Aug;7(Sull):e064430a. doi: 10.1097/01.HS9.0000967492.06443.0a
   Google Scholar
• Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021 Dec 20;39(36):4049–4060. doi: 10.1200/JCO.21.01181
   PubMed Web of Science ®Google Scholar
• Kater AP, Levin M-D, Dubois J, et al. Minimal residual disease guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (Hovon141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23:818–828. doi: 10.1016/S1470-2045(22)00220-0
   PubMed Web of Science ®Google Scholar
• Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021 Dec 1;39(34):3853–3865. doi: 10.1200/JCO.21.00807
   PubMed Web of Science ®Google Scholar
• Molica S, Allsup DJ. Time-limited, chemotherapy-free treatment comes of age in chronic lymphocytic leukaemia. Lancet Oncol. 2022 Jun;23(6):699–701. doi: 10.1016/S1470-2045(22)00266-2
   PubMed Web of Science ®Google Scholar
• Bennett R, Anderson MA, Seymour JF. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia. J Hematol Oncol. 2023 Jul 8;16(1):72. doi: 10.1186/s13045-023-01469-7
   PubMed Web of Science ®Google Scholar
• Blombery P, Anderson MA, Gong J, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342–353.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Tambaro FP. How I manage CLL with venetoclax-based treatments. Blood. 2020;135(17):1421–1427. doi: 10.1182/blood.2019002841
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Niemann CU, Kater AP, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023 May 11;388(19):1739–1754. doi: 10.1056/NEJMoa2213093
   PubMed Web of Science ®Google Scholar
• Vassilopoulos S, Shehadeh F, Kalligeros M, et al. Targeted therapies in CLL/SLL and the cumulative incidence of infection: a systematic review and meta-analysis. Front Pharmacol. 2022 Sep 14;13:989830. eCollection 2022. doi: 10.3389/fphar.2022.989830
   PubMed Web of Science ®Google Scholar
• Kater AP, Eichhorst B, Owen C, et al. Long-term host immune changes following treatment with venetoclax plus rituximab in relapsed/refractory chronic lymphocytic leukemia. Blood. 2022;140(Supplement 1):7010–7012.
   Google Scholar
• Moreno C, Solman IG, Tam CS, et al. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv. 2023;7(18):5294–5303.
   PubMed Web of Science ®Google Scholar
• Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1(7). doi: 10.1056/EVIDoa2200006
   PubMedGoogle Scholar
• Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019 Apr 27;6(2):19. doi: 10.3390/jcdd6020019
   PubMed Web of Science ®Google Scholar
• European Commission approves IMBRUVICA® (ibrutinib) in a fixed-duration combination regimen for adult patients with previously untreated chronic lymphocytic leukaemia (CLL). News Release. Johnson & Johnson. [2022 Aug 4; cited 2022 Aug 25]. Available from: https://bit.ly/3AMP4yh
   Google Scholar
• Niemann CU. BTK inhibitors: safety + efficacy = outcome. Blood. 2023 Aug 24;142(8):679–680. doi: 10.1182/blood.2023020974
   PubMed Web of Science ®Google Scholar
• Molica S. Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy. Expert Rev Hematol. 2023 Oct;13:1–4. Online ahead of print. doi: 10.1080/17474086.2023.2271170
   Google Scholar
• Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017 Jan 10;35(2):166–174. doi: 10.1200/JCO.2016.68.2856
   PubMed Web of Science ®Google Scholar
• Lachaine J, Guinan K, Aw A, et al. Impact of fixed-duration oral targeted therapies on the economic burden of chronic lymphocytic leukemia in Canada. Curr Oncol. 2023;30(5):4483–4498.
   PubMed Web of Science ®Google Scholar